| Name | Title | Contact Details |
|---|
Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
As a clinical-stage pharmaceutical company founded on cutting-edge research, ESSA is focused on developing novel therapeutics for cancer patients. ESSA embraces innovation not only in our products but also in our approach. We re firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.
Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.
Synageva BioPharma Corp. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sartorius Stedim Biotech is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.